Bronchitis is an inflammation of the bronchi, the tubes that carry air in and out of the lungs. The main symptom of bronchitis is a cough that brings up mucus, but it can also cause trouble breathing and chest tightness. When bronchitis keeps coming back or doesn’t go away, it’s called Chronic Bronchitis. Each year, millions of adults are diagnosed with Chronic Bronchitis, and rates are on the rise.
If you’re living with Chronic Bronchitis and still experience symptoms despite your medications, you may qualify for the RheSolve Clinical Study. The study is evaluating Bronchial Rheoplasty using RheOx™, an investigational device designed to reduce cough and mucus production through a minimally-invasive procedure.
What causes Chronic Bronchitis?
In healthy lungs, mucus produced by the bronchi helps clear irritating particles we occasionally inhale. However, if the bronchi are constantly stimulated by cigarette smoke, they produce more and more mucus. Eventually, even after quitting smoking, the bronchi will keep on producing too much mucus, resulting in chronic cough and shortness of breath.
Although medications are available for Chronic Bronchitis, they do not directly target the damaged cells to stop producing mucus. Recently, a new technology has been developed that directly target the mucus-producing cells of the bronchi to reduce cough and mucus production in people with Chronic Bronchitis.
Bronchial Rheoplasty Using RheOx™
RheOx (Gala Therapeutics, Inc.) is an investigational device designed to reduce cough and mucus production through a minimally-invasive procedure. The procedure is performed through a bronchoscope, a thin flexible tube that is inserted through the mouth into the lungs. Once in place, RheOx delivers short bursts of electrical energy to the inner walls of the bronchi, eliminating the mucus-producing cells. Over the next several days, new cells grow and produce less mucus. The right lung is treated first, followed by treatment of the left lung about 1 month later.
RheOx has been studied in three clinical trials and has shown a significant improvement in quality of life and a reduction in cough and mucus at 12 months.1
RheOx is currently being offered at select centers in the US, Canada, and Europe through a new clinical research study called the RheSolve Study.
If you’re living with Chronic Bronchitis and still experience symptoms despite your medications, you may qualify for the RheSolve Study. The study is evaluating Bronchial Rheoplasty using RheOx™, an investigational device designed to reduce cough and mucus production through a minimally-invasive procedure.
If you qualify and choose to join the study, you may receive:
The RheSolve Study is sponsored by Gala Therapeutics, Inc.
See If You Qualify
To see if you might qualify for the RheSolve Study, and to get connected with your local study center to learn more, please take the questionnaire below.
Valipour, A. et al. Bronchial Rheoplasty For Treatment of Chronic Bronchitis: 12 Month Results from a Multi-Center Study. American Journal of Respiratory and Critical Care Medicine 2020; Volume 202, Number 5. Gala data on file: CER-00001 Rev A Clinical Evaluation Report, CS003 Study Report 21OCT2020, CS004 Study Report 21OCT2020.